United Therapeutics Corporation secured a second phase 3 trial win for its nebulized drug Tyvaso in treating idiopathic pulmonary fibrosis (IPF), showing significant lung function improvement. The company plans to submit a supplemental new drug application (sNDA) by summer and seek Priority Review for Tyvaso in IPF. Tyvaso's 2025 revenues grew 16% to $1.878 billion, contributing to United Therapeutics surpassing $3 billion in total revenue despite a slight Q4 sales miss. Ongoing trials aim to expand Tyvaso's use to progressive pulmonary fibrosis, indicating strong growth potential for the company.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
NVIDIA and Noetra Corp. are partnering to build Japan's first national AI infrastructure, the NVIDIA Vera Rubin AI factory, featuring 13,750 Vera CPUs and 27,500 Rubin GPUs. Supported by Japan's Ministry of Economy, Trade and Industry, this 140-megaw...
Solana (SOL) has gained about 30% from its June low, trading around $78 and surpassing its 50-day EMA. The token's upward momentum is supported by increased speculative trading and a new SuperTrend buy signal, the first since October 2025. However, i...
Kenmare Resources reported weaker-than-expected production in the first half of 2026 due to commissioning delays at its Wet Concentrator Plant A, with ilmenite output down 40% year on year in Q2. Despite this, shipments increased by 53% as the compan...
